Lead Pharma, Sanofi strike RORgammaT deal

Lead Pharma Holding B.V. (Nijmegen, the Netherlands) and Sanofi (Euronext:SAN; NYSE:SNY) partnered to develop small molecule inhibitors of RAR-related orphan receptor C thymus-specific isoform ( RORgamma2; RORgammaT) to treat autoimmune disorders including rheumatoid arthritis (RA) and inflammatory bowel disease (IBD).

Sanofi is responsible for clinical development of candidates covered by the deal, and will have global marketing and commercialization rights to any products arising from the partnership. ...